Therapeutic | Isatuximab |
Target | CD38 |
Heavy Chain | QVQLVQSGAEVAKPGTSVKLSCKASGYTFTDYWMQWVKQRPGQGLEWIGTIYPGDGDTGYAQKFQGKATLTADKSSKTVYMHLSSLASEDSAVYYCARGDYYGSNSLDYWGQGTSVTVSS |
Light Chain | DIVMTQSHLSMSTSLGDPVSITCKASQDVSTVVAWYQQKPGQSPRRLIYSASYRYIGVPDRFTGSGAGTDFTFTISSVQAEDLAVYYCQQHYSPPYTFGGGTKLEIK |
100% seqID Fv Structure | 4cmh [Fvs: BC] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4cmh [Fvs: BC] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (June '19) | Preregistration |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | ImmunoGen, Huntsman Cancer Institute, Roche, Sanofi |
Conditions Approved | na |
Conditions Active | Multiple myeloma, Acute myeloid leukaemia, Precursor cell lymphoblastic leukaemia-lymphoma, T-cell lymphoma, Colorectal cancer, Diffuse large B cell lymphoma, Hodgkin's disease, Non-small cell lung cancer, Peripheral T-cell lymphoma, Prostate cancer, Solid tumours, Urogenital cancer |
Conditions Discontinued | na |
Notes |